Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Furazabol
- DrugBank Accession Number
- DB01514
- Background
Not Available
- Type
- Small Molecule
- Groups
- Illicit
- Structure
Structure for Furazabol (DB01514)
- Weight
- Average: 330.4644
Monoisotopic: 330.230728214 - Chemical Formula
- C20H30N2O2
- Synonyms
- Furazabol
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Miotolon (Daiichi)
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Estrane steroids
- Direct Parent
- Estrane steroids
- Alternative Parents
- 17-hydroxysteroids / Tertiary alcohols / Heteroaromatic compounds / Furazans / Cyclic alcohols and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- 17-hydroxysteroid / Alcohol / Aromatic heteropolycyclic compound / Azacycle / Azole / Cyclic alcohol / Estrane-skeleton / Furazan / Heteroaromatic compound / Hydrocarbon derivative
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2W07HSP5PX
- CAS number
- 1239-29-8
- InChI Key
- RGLLOUBXMOGLDQ-IVEVATEUSA-N
- InChI
- InChI=1S/C20H30N2O2/c1-18-11-17-16(21-24-22-17)10-12(18)4-5-13-14(18)6-8-19(2)15(13)7-9-20(19,3)23/h12-15,23H,4-11H2,1-3H3/t12-,13+,14-,15-,18-,19-,20-/m0/s1
- IUPAC Name
- (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6-oxa-5,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4,7-dien-17-ol
- SMILES
- [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NON=C3C[C@]12C
References
- Synthesis Reference
Ohta, G., Takegoshi,T., Onodera, T., Kasahara, A., Oshima, Y., Shimizu, M. and Ueno, K.; U.S. Patent 3,245,988; April 12,1966; assigned to Daiichi Seiyaku KK, Japan.
- General References
- Not Available
- External Links
- PubChem Compound
- 14708
- PubChem Substance
- 46505276
- ChemSpider
- 14032
- ChEBI
- 31640
- ChEMBL
- CHEMBL1893554
- ZINC
- ZINC000004216375
- Wikipedia
- Furazabol
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 152 Ohta, G., Takegoshi,T., Onodera, T., Kasahara, A., Oshima, Y., Shimizu, M. and Ueno, K.; U.S. Patent 3,245,988; April 12,1966; assigned to Daiichi Seiyaku KK, Japan. - Predicted Properties
Property Value Source Water Solubility 0.0277 mg/mL ALOGPS logP 4.3 ALOGPS logP 2.97 Chemaxon logS -4.1 ALOGPS pKa (Strongest Basic) -0.51 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 59.15 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 93.06 m3·mol-1 Chemaxon Polarizability 37.94 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9564 Caco-2 permeable + 0.5836 P-glycoprotein substrate Substrate 0.7034 P-glycoprotein inhibitor I Non-inhibitor 0.5547 P-glycoprotein inhibitor II Non-inhibitor 0.9066 Renal organic cation transporter Non-inhibitor 0.7822 CYP450 2C9 substrate Non-substrate 0.7399 CYP450 2D6 substrate Non-substrate 0.7865 CYP450 3A4 substrate Substrate 0.6629 CYP450 1A2 substrate Non-inhibitor 0.5561 CYP450 2C9 inhibitor Non-inhibitor 0.7852 CYP450 2D6 inhibitor Non-inhibitor 0.89 CYP450 2C19 inhibitor Non-inhibitor 0.6522 CYP450 3A4 inhibitor Non-inhibitor 0.6092 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7734 Ames test Non AMES toxic 0.6452 Carcinogenicity Non-carcinogens 0.8767 Biodegradation Not ready biodegradable 0.9941 Rat acute toxicity 1.9483 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8085 hERG inhibition (predictor II) Non-inhibitor 0.7679
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0019000000-29431bb322ef2a0dcee2 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-01q9-3978000000-0604e6473c170db0fee1 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0009000000-d6dbae6a3b3ab70a62f1 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0009000000-f53e1e358f3d54404b6e Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-5921000000-5f44a66498e6a3afdb04 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-08i1-2079000000-91a53661264ae63791aa Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 185.521558 predictedDarkChem Lite v0.1.0 [M-H]- 180.85188 predictedDeepCCS 1.0 (2019) [M+H]+ 185.682158 predictedDarkChem Lite v0.1.0 [M+H]+ 182.74728 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.52524 predictedDeepCCS 1.0 (2019)
Drug created at July 31, 2007 13:10 / Updated at February 21, 2021 18:51